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Abstract
Background: People with Parkinson disease (PD), even in the presence of symptomatic relief from medical,
surgical, and rehabilitative interventions, face a persistent worsening of disability. This disability is characterized by
diminished quality of life, reduced functional mobility, declining performance in activities of daily living and
worsening neurological impairments. While evidence has emerged supporting the clinically meaningful benefits of
short-term exercise programs on these underlying factors, assertions regarding the effects of sustained programs of
exercise and physical activity on the trajectory of disablement in PD are made in the absence of direct evidence.
Indeed, the natural decline in quality of life and functional mobility in people diagnosed with PD is poorly
understood. Moreover, outcome measures commonly used in clinical exercise trials typically do not capture the full
spectrum of disability as defined by the World Health Organization (WHO).
Methods/Design: The objective of this multicenter prospective study will be to examine the 2-year trajectory of
disablement in a cohort of persons with PD. Two hundred sixty participants will be recruited to produce an
expected final sample size of 150 individuals. Participants will be included if they are greater than 40 years of age,
have a neurologist confirmed diagnosis of idiopathic PD, and are at Hoehn and Yahr stages 1 through 4. Data will
be collected every 6 months during the study period. Primary outcome measures reflecting a broad spectrum of
disablement will include, but will not be limited to, MDS-UPDRS, Timed Up and Go, Berg Balance Test, Nine Hole
Peg Test, PDQ-39, and directly monitored ambulatory activity. Self-reported exercise and physical activity data also
will be recorded. Statistical analyses will be used to characterize the trajectory of disablement and examine the
influence of its underlying contributing factors.
Discussion: Tertiary prevention is an important component of contemporary healthcare for individuals living with
degenerative disease. For individuals with PD, there is growing recognition that exercise and/or physical activity
efforts to slow the rate of functional mobility decline, in particular, may be critical for optimizing quality of life. By
describing the natural trajectory of disablement, exercise habits, and physical activity in a cohort of persons with
PD, this investigation will establish an important foundation for future intervention research. Specifically, through
the evaluation of the influence of sustained exercise and physical activity on disablement, the study will serve as a
preliminary step toward developing a randomized controlled trial of long-term exercise in persons with PD.
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Background
Parkinson disease (PD) is a chronic, progressive neuro-
degenerative disease affecting more than 4 million peo-
ple world-wide [1]. With adequate access to healthcare
services, persons with PD can live 20-30 years following
initial diagnosis [2]. Nonetheless, persons with PD face a
persistent deterioration in functional mobility and activ-
ities of daily living often resulting in a loss of indepen-
dence and a decline in quality of life.
Over the last decade, a growing body of evidence has
emerged revealing significant and clinically meaningful
benefits of exercise for addressing PD-related problems.
For example, a critical review of the literature identified 23
randomized controlled trials demonstrating that patients
who participated in exercise programs had better quality
of life, walking ability, balance, strength, flexibility and car-
diovascular fitness compared to those who did not exer-
cise[3]. Exercise studies of both rodent and primate
models of PD have demonstrated increased survival of
nigrostriatal dopaminergic neurons, suggesting a potential
protective effect of exercise as well[4,5]. Furthermore, a
prospective epidemiological study revealed a significant
decreased risk of developing PD in people who partici-
pated in moderate to vigorous exercise[6,7].
Although promising, studies of exercise in PD have
been limited in scope. Most have examined the effects
of short-term exercise programs, typically implemented
over 4 to 12 weeks. Furthermore, in studies with pro-
longed follow-up, exercise benefits typically attenuated
over weeks to months following the intervention period
[8,9]. Thus, the benefit of longer, more sustained pat-
terns of regular exercise on PD-related problems
remains poorly understood. In particular, the impact of
sustained exercise and/or a physically active lifestyle on
the rate at which persons with PD become disabled (i.e.,
the “trajectory of disablement”) remain unknown.
Currently the Unified Parkinson Disease Rating Scale
(UPDRS) and its most recent version (the MDS-UPDRS)
are considered the gold standards for examining disease
severity and progression[10-12]. The UPDRS focuses
primarily on measuring impairments associated with
PD, with fewer items addressing specific functional lim-
itations or perceptions of quality of life. The subsections
of the UPDRS are organized according to motor and
non-motor aspects of the disease, significantly limiting
the assessment of disablement in PD. As a result, the
burden of PD is commonly understood more in terms
of disease progression (i.e., the predictable evolution of
signs, symptoms, and impairments) rather than in terms
of the potentially diverse paths through which persons
with PD become disabled.
In contrast to the UPDRS, the International Classifica-
tion of Functioning, Disability, and Health (ICF) was
developed as a framework for understanding disability at
multiple levels[13]. Accordingly, the effect of health con-
ditions (e.g., PD) is considered across 3 domains of
human function: body structure and function, activity,
and participation. “Disability” is used to denote a decre-
ment at each level (i.e., a body structure or function
impairment, an activity limitation, and a participation
restriction)[13]. Underscoring the value of this approach,
the World Health Organization (WHO) endorsed the
ICF in 2001[14].
“Body structure,” in ICF terms, is defined as an anato-
mical part of the body, such as organs, limbs and their
components, while “body function” is defined as the
physiological function of body systems. Applied to PD,
motor signs such as bradykinesia, tremor and rigidity
represent impairments in body structure and function.
“Activity” is defined as the execution of a task or action
by an individual and activity limitations as the difficul-
ties an individual may have in executing such tasks.
Activity limitations common in PD are those affecting
gait, balance, getting dressed, bathing, and other activ-
ities of daily living. Lastly, “participation” is defined as
the involvement in a life situation and participation
restrictions as problems an individual may experience in
involvement in life situations. Participation restrictions
in PD may include involvement in leisure, work or
social aspects of life in both the household and commu-
nity settings[14].
To address the aforementioned limitations in the exer-
cise and disability literature, we plan to conduct a
2-year, multicenter prospective longitudinal study of a
cohort of persons with PD. The objectives of the study
will be: (1) to characterize the natural trajectory of dis-
ablement using a spectrum of measures organized
according to the ICF framework, and (2) to identify
potential factors, including but not limited to those
related to exercise and physical activity, that contribute
to the development of impairments of body structure/
function, activity limitations, or participation restric-
tions. The study is anticipated to lay an important foun-
dation for future studies, especially those designed to
understand the impact of sustained exercise and/or a
physically active lifestyle on disablement in PD.
Methods/Design
Research Design
The proposed project is a prospective, longitudinal
cohort study in which patients with PD will be assessed
every 6 months over a 2-year period using a specific
battery of outcome measures designed to reflect the full
spectrum of disability.
Participants and Recruitment
Two hundred sixty participants will be recruited
through the Neurology Department at the University of
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Utah, the Parkinson’s Disease and Movement Disorder
Center at Boston University Medical Center (BU
PDMC), the Department of Neurology at the University
of Alabama at Birmingham (UAB), and the Movement
Disorders Center at Washington University in St Louis
School of Medicine. Prior to data collection, ethics
approval will be achieved through the Institutional
Review Board (IRB) at each participating site. Before
participation, all participants will sign IRB approved
informed consent forms. Gathering data at four sites
will promote rapid enrollment and increase the
likelihood of enrolling participants who typically are
under-represented in PD studies (e.g., Ethnic minority
participants, females, individuals who are at Hoehn and
Yahr Stage 4). Included participants will be community
dwelling persons ≥ 40 years of age who have neurolo-
gist-diagnosed idiopathic PD (using UK Brain Bank Cri-
teria [15]), are at Hoehn and Yahr stages I-IV (mild to
moderate disease severity), and score ≥ 24/30 on the
Mini-mental State Examination. Excluded participants
will be individuals with a diagnosis of atypical Parkin-
sonism, who are at Hoehn and Yahr stage 5, or who
have had previous surgical management of PD (e.g. pal-
lidotomy, deep brain stimulation).
Power and Sample Size Estimates
A 25% annual attrition rate is anticipated over the 2-
year study period, resulting in a final estimated sample
size of 150 participants. The final sample will be suffi-
cient to provide precise disability estimates and to allow
for the inclusion of as many as 12 predictor variables in
multiple regression analyses that evaluate the underlying
contributors to various trajectories of disablement (a =
0.05; N ≥ 50 + 8 (X), where X = the number of predic-
tor variables.)[16]
Procedures
At baseline, demographic information and disease his-
tory will be collected via interview. At each measure-
ment interval (i.e., baseline, 6 months, 1 year, 1.5 years
and 2 years), (1) co-morbidity data will be collected
using a modified version of the Comorbidity Question-
naire, a reliable and valid instrument that offers practical
advantages over medical record based assessments [17];
(2) depression will be assessed using the Geriatric
Depression Scale [18,19]; and (3) medication data (i.e.,
drug name, dose, frequency, levo-dopa equivalence) will
be collected using a customized form. In addition, a
suite of standardized instruments will be employed at
each measurement interval to capture participant physi-
cal function, mobility, physical activity, and quality of
life. The instruments have been selected for their strong
psychometric properties and collective representation of
ICF domains (Table 1 and Figure 1)
Measure of Body Structure and Function
Sections I and III of the MDS-UPDRS will be utilized to
assess neurological signs[10,12]. Section I, which is
entitled “Non-motor aspects of experiences of daily liv-
ing”, consists of 13 items that will be administered via
clinician interview and a participant/caregiver question-
naire. Section III consists of 18-items pertaining to
motor aspects of the disease, the data for which will be
obtained by examining the participant at the time of
each visit. Each item is rated on a 5-point (0-4) ordinal
scale, with higher scores indicating more severe
impairment.
Measures of Activity
(1) Section II of the MDS-UPDRS consists of 13 items
related to activities of daily living (ADL). Data will be
obtained via interview. Each item is rated on a 5-point
(0-4) ordinal scale with higher scores indicating more
severe activity limitation. The UPDRS has been adminis-
tered in several large clinical trials in PD and is reliable,
valid and responsive to change[10,12].
(2) The Berg Balance Scale (BBS) is a 14-item test bat-
tery that quantitatively assesses balance and risk for falls
through direct observation of performance[20]. The BBS
requires approximately 15 minutes to complete and
measures the participant’s ability to maintain balance
either statically or dynamically over a specified period of
time[21]. The items are scored on a 5-point (0-4) ordi-
nal scale. The total score, which will be used as the
dependent variable, ranges from 0 to 56 with higher
scores indicating better balance. Validity and high test-
retest reliability of the BBS total score have been
Table 1 Battery of Outcome Measures
ICF Disablement Construct Outcome Variable
Body Structure and Function
MDS-UPDRS Sections I, III
Activity
6 Minute Walk Test
9 Hole Peg Test
Berg Balance Scale
Freezing of Gait Questionnaire
Functional Gait Assessment
Gait Speed (10 meter walk)
MDS-UPDRS Section II
Timed Up and Go
Participation
Ambulatory Activity
PASE
PDQ-39
MDS-UPDRS = Movement Disorders Society-Unified Parkinson Disease Rating
Scale; PASE = Physical Activity Scale for the Elderly; PDQ-39 = Parkinson
Disease Questionnaire - 39.
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demonstrated across a variety of populations including
patients with PD[22,23].
(3) The Functional Reach Test (FR) measures the
maximum distance a participant can reach in the for-
ward direction with a fixed base of support[24]. Each
participant will be asked to make a fist, raise the domi-
nant arm parallel to the floor and reach as far forward
as possible without taking a step. Using a yardstick
mounted on the wall at the shoulder height and the
third metacarpal as the reference point, the distance
between the starting and ending position will be
recorded. Two practice trials and 3 test trials will be
conducted, with the mean distance reached during the 3
test trials used as the dependent variable. Validity and
high test-retest reliability of the FR have been estab-
lished in healthy elders and in people with PD [23,24].
(4) The Functional Gait Assessment (FGA) is a 10-
item standardized test for assessing postural stability
Figure 1 Flow sheet of Study Procedures. Abbreviations: UAB = University of Alabama at Birmingham, MDS-UPDRS = Movement Disorders
Society-Unified Parkinson Disease Rating Scale, FOG-Q = Freezing of Gait Questionnaire, PDQ-39 = Parkinson Disease Questionnaire - 39, PASE =
Physical Activity Scale for the Elderly.
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during various walking tasks. Items include walking with
head turns, walking with eyes closed, walking while
altering gait speed, walking in a backward direction,
walking with a narrowed base of support, negotiating
obstacles, stopping, turning and stair climbing. Items are
scored using a 4-point ordinal scale (0-3). Total score,
which will be used as the dependent variable, ranges
from 0 to 30, with higher scores indicating better per-
formance. Reliability, internal consistency and validity of
the FGA total score have been established in healthy
adults and in patients with neurological disorders[25,26].
(5) The six-minute walk (6MW) test, a measure of the
distance a participant walks in 6 minutes, will be used
to assess overall locomotor ability. The 6MW distance is
related to functional movement tasks and is an indepen-
dent predictor of prognosis in older patients with co-
morbid conditions. The 6MW’s test-retest reliability is
high, ranging from .94 - .96, in older populations with
various co-morbid conditions[23,27].
(6) Self-selected and maximal pace gait speed will be
measured during a 10 meter walk. Three trials at each
pace will be recorded, with the average speed at each
pace used as separate dependent variables. Gait speed
provides a standardized measure of gait function that
has been found to be reliable and is sensitive to change
over a broad range of physical function in elderly indivi-
duals and persons with neurologic pathology[23,27,28].
(7) The Freezing of Gait Questionnaire (FOG-Q) is a
valid and reliable 6-item tool used to assess the severity
of freezing of gait in patients with PD[29,30]. Each item
is rated on a 5-point ordinal scale, from 0 (absence of
symptom) to 4 (most severe symptom). The total score,
which will be used as the dependent variable, reflects
the sum of the 6 items and ranges from 0-24. The
FOG-Q will be self-administered by all participants.
(8) The “Timed Up and Go” Test (TUG) measures the
time it takes for a participant to stand from a seated
position in an armchair, walk forward 3 m at a comfor-
table pace, turn around, walk back to the chair, and sit
down. Each participant will perform a practice trial fol-
lowed by 2 test trials. The mean of the 2 test trials will
be the dependent variable. In older adults at risk for
falls, the TUG has been found to possess excellent intra
and inter-tester reliability (.94-.96) and predictive valid-
ity in that increased times on the TUG relate to
increased fall-risk[23,31,32].
(9) The Nine Hole Peg Test (9-HPT) is a brief, stan-
dardized, quantitative test of upper extremity function
that asks the participant to place and remove nine pegs
one at a time, as quickly as possible, from nine holes in
a peg board. Scoring is determined by the total time to
complete the task. Two trials with the dominant hand
will be immediately followed by two trials with the non-
dominant hand. The mean of the two trials for each
hand will be the dependent variable. The 9-HPT has
high inter-rater reliability and good test-retest reliability.
There is evidence for concurrent and convergent validity
as well as sensitivity to detect minor impairments of
hand function[33,34].
Measures of Participation
(1) The Parkinson’s Disease Questionnaire-39 (PDQ-39)
is a health status instrument that contains 39-self-report
items and was specifically developed for people with
Parkinson’s disease. The PDQ-39 measures the degree
of healthy, competent, and satisfying participation in
daily life activities. The reliability, validity, and sensitivity
to change of the PDQ-39 have been established in com-
munity dwelling persons with PD. In addition to the
composite summary score, we will utilize the 8 sub-
scores (i.e., mobility, activities of daily living, emotions,
stigma, social support, cognition, communication, and
body discomfort) to reflect constructs that have been
consistently found to contribute to perceived quality of
life in persons with PD)[35-37].
(2) Ambulatory Activity: To capture “free-living”
ambulatory activity, a sub-group of participants will
wear a StepWatch 3 Activity Monitor (SAM, Orthocare
Innovations, Seattle, WA,), 24 hours per day for 7 con-
secutive days, except when bathing, showering, or swim-
ming. The SAM is approximately the size of a pager,
weighs 38 g, and is attached using Velcro closures
immediately proximal to the lateral malleolus of either
leg. The SAM uses a combination of acceleration, posi-
tion, and timing to detect steps taken by the leg on
which it is worn. It is designed for long-term use during
daily activities performed in an individual’s customary
environment over hours or days without maintenance
by the user. Data are recorded as a temporal series of
counts, with each data point representing the number of
steps per one-minute interval. Data will be downloaded
to a personal computer via an infrared docking station
and post processed using either manufacturer software
or custom analysis programs written in Matlab (Math-
works, Natick, MA). Step counts will be used to gener-
ate multiple indices of mean daily ambulatory activity (e.
g., total number of steps, percent of day spent inactive,
total number of bouts of activity, bout duration, and
activity intensity). The SAM is particularly accurate for
individuals with impaired gait, is unobtrusive and easy
to use, and has demonstrated good test-retest reliability
(ICC, r = 0.84) and accuracy (98%) in an older adult
population[38-42].
(3) The Physical Activity Scale for the Elderly (PASE)
measures the level of self-reported physical activity in
individuals aged 65 years or older and is comprised of
items regarding occupational, household, and leisure
activities during the previous 7-day period[43,44].
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Leisure activities include frequency and duration of
walking outside the home, as well as participation in
light, moderate and strenuous exercise. The total PASE
score, which will be used as the dependent variable, is
computed by multiplying the time spent in each activity
(hours/week) or participation (yes/no) in an activity by
empirically derived item weights and summing over all
activities. The PASE has previously been validated in
elderly populations[45-47].
Statistical Analysis Plan
Confidence intervals, means, standard deviations and
frequency distributions will be calculated for all mea-
sures. Corrections for multiple comparisons will be used
to control for increased type I statistical error risk.
Effect sizes and post hoc power will be calculated when
appropriate. All analyses will be performed with SPSS
16.0 (SPSS Inc).
To address study objective 1, disablement trajectory
will be characterized using interval and point estimators
of each outcome measure. In addition, survival analyses
will be utilized to examine the time to reach operation-
ally defined mobility thresholds (i.e., limited community
ambulatory gait speed, assistance with ADL’s, time to
recurrent falls). This approach will allow us to charac-
terize the distribution of time-to-event data, to test for
differences between subgroups (i.e., exercise history, dis-
ease severity, disease sub-type, age, number of cormor-
bidities), and to utilize regression models to analyze
complex influences of covariates on time to event data
[16].
To address study objective 2, multiple regression ana-
lyses will be conducted to identify those factors asso-
ciated with progression of disability. Assessments for
violation of assumptions will be made, including ana-
lyses of normality of the residuals and linearity of the
continuous variables[16]. As needed, potentially more
potent contributors will be used to define subgroups
within the sample (e.g., exercisers vs. non-exercisers;
physically active vs. sedentary), and analyses of variance
will be used to evaluate between- and within-group dif-
ferences in disablement change.
Data management
The multicenter protocol will rely on a web-based sys-
tem of data input into a central database. The system
will feature multi-tiered security-protected access and
will conform to HIPAA security policies. Stored data
will be backed up daily. Authenticated investigators will
have access to the dataset from any Internet access
point.
Prior to data collection, study personnel at each site
will review a standard operating procedures (SOP) pro-
tocol manual and will rate two standardized persons
with PD, who will have been filmed performing the bat-
tery of physical performance tests. Study personnel and
site specific ratings will be evaluated by the data man-
agement team to insure their accuracy and consistency.
At each measurement interval, data will be collected
on paper forms and entered into the web-based data
entry portal by a specific individual at each site. The
data management team subsequently will confirm the
accuracy of data entry for every third participant by
comparing electronic data with the original hard copy
data. In addition, the team will select files at random for
similar review. Researchers at each site will be notified
of any discrepancies or incomplete data.
Discussion
Tertiary prevention is an important component of con-
temporary healthcare for individuals with degenerative
disease. Yet only recently has attention been given to
the evolution of disability among persons with PD
[13,48-51]. Such studies, however, while valuable, have
been limited by cross-sectional designs and limited
scope of disablement. To our knowledge, our proposed
study is novel for its longitudinal examination of the
natural trajectory of disablement, exercise habits, and
physical activity in a cohort of persons with PD. In this
context, data collected in the study will provide a foun-
dation for future exercise intervention research. Not
only will the study characterize disablement using a
broad spectrum of measures, it also has the potential to
identify factors that might influence, either positively or
negatively, the rates at which persons with PD experi-
ence decline in mobility and quality of life.
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